GlassScriptPhysician profile
Julia C Liepmann
NPI 1720268576
$2,661.26
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,241 · 2022: $421.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $566.84 | 2021-2022 | |
| Abbvie INC. | $439.93 | 2021-2022 | |
| Viiv Healthcare Company | $309.18 | 2021-2022 | |
| Novo Nordisk INC | $223.13 | 2021-2022 | |
| Bausch Health US, LLC | $156.31 | 2021 | |
| Amgen INC. | $133.42 | 2021 | |
| Gilead Sciences, INC. | $80.53 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.50 | 2021 | |
| Esperion Therapeutics, INC. | $74.78 | 2021 | |
| Lilly USA, LLC | $55.45 | 2021 | |
| Biogen, INC. | $48.75 | 2021-2022 | |
| Glaxosmithkline, LLC. | $48.05 | 2021 | |
| Octapharma USA, INC. | $45.71 | 2021 | |
| Lundbeck LLC | $44.56 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $44.46 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $43.56 | 2021 | |
| Clarus Therapeutics INC. | $37.40 | 2021 | |
| Currax Pharmaceuticals LLC | $33.49 | 2021 | |
| Antares Pharma, INC. | $30.96 | 2021 | |
| Redhill Biopharma INC. | $30.19 | 2021 | |
| Amarin Pharma, INC. | $22.72 | 2021 | |
| Ironwood Pharmaceuticals, INC | $22.01 | 2021 | |
| Akcea Therapeutics, INC. | $20.78 | 2021 | |
| Horizon Therapeutics Plc | $20.03 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.99 | 2021 | |
| Janssen Biotech, INC. | $15.86 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.67 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Liepmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.